4//SEC Filing
Keson-Brookes Maiken 4
Accession 0000950170-25-033769
CIK 0001971543other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 4:49 PM ET
Size
11.8 KB
Accession
0000950170-25-033769
Insider Transaction Report
Form 4
Keson-Brookes Maiken
See Remarks
Transactions
- Award
Ordinary Shares
2025-03-03+35,000→ 76,295 total - Sale
Ordinary Shares
2025-03-04$3.36/sh−1,262$4,240→ 75,033 total - Sale
Ordinary Shares
2025-03-05$3.45/sh−1,469$5,068→ 73,564 total - Award
Stock Option (right to buy)
2025-03-03+65,000→ 65,000 totalExercise: $3.43Exp: 2035-03-02→ Ordinary Shares (65,000 underlying)
Footnotes (6)
- [F1]Consists of ordinary shares issuable under 35,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of March 1, 2025, subject to the reporting person's continued service with the Issuer.
- [F2]Includes 34,505 unvested restricted stock units
- [F3]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 1, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on December 22, 2023, and the sale does not represent a discretionary trade by the Reporting Person.
- [F4]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.36. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]Represents shares automatically sold by the Reporting Person pursuant to a Rule 10b5-1 trading arrangement that was entered into by the Reporting Person on September 20, 2024.
- [F6]This option was granted on March 3, 2025. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on March 1, 2026 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued services with the Issuer.
Documents
Issuer
Mural Oncology plc
CIK 0001971543
Entity typeother
Related Parties
1- filerCIK 0001693805
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 4:49 PM ET
- Size
- 11.8 KB